NCT07321951

A Study of SHR-1819 in Patients With Moderate-to-severe Atopic Dermatitis

A Multicenter, Randomized, Double-blind, Phase II Study to Evaluate the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This trial was designed to evaluate the efficacy and safety of SHR-1819 in adult patients with moderate-to-severe atopic dermatitis.

Conditions

• Moderate-to-severe Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	SHR-1819 Injection	SHR-1819 injection.
DRUG	SHR-1819 Injection Blank Preparation	SHR-1819 injection blank preparation.

Timeline

• Start date: 2026-01-09
• Primary completion: 2027-06-01
• Completion: 2027-08-01
• First posted: 2026-01-07
• Last updated: 2026-04-08

Locations

2 sites across 1 country: China